Difference between revisions of "HAEM5:Monoclonal immunoglobulin deposition disease"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[checked revision][checked revision]
 
Line 15: Line 15:
 
__TOC__
 
__TOC__
  
−
==Cancer Category / Type==
+
==WHO Classification of Disease==
  
−
*[https://ccga.io/index.php/HAEM4:Mature_B-Cell_Neoplasms Mature B-cell neoplasms]
+
{| class="wikitable"
−
 
+
!Structure
−
==Cancer Sub-Classification / Subtype==
+
!Disease
−
 
+
|-
−
*[https://ccga.io/index.php/HAEM4:Monoclonal_Immunoglobulin_Deposition_Diseases Monoclonal immunoglobulin deposition disease]
+
|Book
 +
|Haematolymphoid Tumours (5th ed.)
 +
|-
 +
|Category
 +
|B-cell lymphoid proliferations and lymphomas
 +
|-
 +
|Family
 +
|Plasma cell neoplasms and other diseases with paraproteins
 +
|-
 +
|Type
 +
|Diseases with monoclonal immunoglobulin deposition
 +
|-
 +
|Subtype(s)
 +
|Monoclonal immunoglobulin deposition disease
 +
|}
  
 
==Definition / Description of Disease==
 
==Definition / Description of Disease==

Latest revision as of 17:33, 6 September 2024

Haematolymphoid Tumours (WHO Classification, 5th ed.)

editContent Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Light Chain and Heavy Chain Deposition Disease.

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

Chen Yang, MD, PhD, University of Michigan

WHO Classification of Disease

Structure Disease
Book Haematolymphoid Tumours (5th ed.)
Category B-cell lymphoid proliferations and lymphomas
Family Plasma cell neoplasms and other diseases with paraproteins
Type Diseases with monoclonal immunoglobulin deposition
Subtype(s) Monoclonal immunoglobulin deposition disease

Definition / Description of Disease

Light Chain and Heavy Chain Deposition Disease is defined as follows[1][2][3][4]:

  • Systemic disorder with non-amyloid deposits of monoclonal immunoglobulin (Ig) in various organs
  • Underlying diseases are HAEM4:Plasma Cell Neoplasms (PCN, >95%) or lymphoplasmacytic neoplasms (2-3%)
  • 20-35% have non-smoldering HAEM5:Plasma cell myeloma / multiple myeloma (PCM), and rest (65-75%) have smoldering plasma cell myeloma or Monoclonal Gammopathy of Uncertain Significance (MGUS)/monoclonal gammopathy of renal significance (MGRS)

Synonyms / Terminology

  • Randall type monoclonal immunoglobulin deposition disease
  • Light chain deposition disease (LCDD)
  • heavy chain deposition disease (HCDD)
  • light and heavy chain deposition disease (LHCDD)

Epidemiology / Prevalence

The following epidemiologic features have been observed[5][6][7][8]:

  • Vary rare
  • Median age: 56-58 years (range: 20-91)
  • 60% are men
  • No ethnic difference
  • Deposited Ig can be light chain (LCDD, ~80%), heavy chain (HCDD, ~10%), or both (LHCDD, ~10%)

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table. Do not delete table.)

Signs and Symptoms EXAMPLE: Asymptomatic (incidental finding on complete blood counts)

EXAMPLE: B-symptoms (weight loss, fever, night sweats)

EXAMPLE: Fatigue

EXAMPLE: Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE: Cytopenias

EXAMPLE: Lymphocytosis (low level)


editv4:Clinical Features
The content below was from the old template. Please incorporate above.

The following clinical and laboratory findings may be seen[5][6][7][8][9][10]:

Signs & Symptoms

  • Organ dysfunction resulting from systemic Ig deposition
  • Renal dysfunction (renal insufficiency, proteinuria, hematuria, and hypertension) in almost all cases
  • Renal failure eventually without treatment
  • Extrarenal symptoms (10-35%) from IG deposition in heart, liver, peripheral nerves, lung, skin, blood vessels, and occasionally joints
  • Diastolic heart failure and atrial arrhythmias if heart involved
  • Hepatomegaly, portal hypertension and liver failure if liver involved
  • Cough, oxygen desaturation and dyspnea if lung involved
  • Peripheral and autonomic neuropathy if nerve involved

Laboratory findings

  • Abnormal serum free light chain ratio in almost all cases
  • M-protein detected on SPEP in majority (70-85%) cases
  • IgG followed by light chain, IgA and IgM, as the most common monoclonal Ig detected in serum
  • The tissue immunoglobulin deposits can differ from the monoclonal Ig in serum
  • Hypocomplementemia in HCDD, due to complement fixation by IgG3 and IgG1 subclasses
  • Septal thickening on echocardiogram if heart involved
  • Elevated liver function test results if liver involved

Sites of Involvement

The following anatomic sites of involvement have been reported[6][7][8][9]:

  • Kidney is nearly always involved
  • Extrarenal organs (heart, liver, peripheral nerves, lung, skin, and blood vessels) involve in 10-35% cases
  • Extrarenal involvement is more common in LCDD with PCM
  • Basement membranes and elastic and collagen fibers are the prominent deposition sites

Morphologic Features

  • Most cases are associated with PCM or MGUS[5], and rarely with HAEM5:Lymphoplasmacytic lymphoma, marginal zone lymphoma, or HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma
  • The smooth, ribbon-like linear Ig deposits consist of Congo red-negative amorphous eosinophilic material that is non-amyloid and non-fibrillary
  • Deposition of Ig is mostly found on renal biopsies but can be observed in bone marrow and other tissues
  • The renal biopsy typically (in 2/3 of cases) shows nodular sclerosing glomerulonephritis
  • Ig predominantly deposits along tubular basement membranes (TBM) and glomerular basement membranes (GBM) under kidney immunofluorescence stain[6]

Immunophenotype

Put your text here and fill in the table (Instruction: Can include references in the table. Do not delete table.)

Finding Marker
Positive (universal) EXAMPLE: CD1
Positive (subset) EXAMPLE: CD2
Negative (universal) EXAMPLE: CD3
Negative (subset) EXAMPLE: CD4


editv4:Immunophenotype
The content below was from the old template. Please incorporate above.

Findings are similar to those of the underlying condition (e.g., Plasma Cell Neoplasm, HAEM5:Lymphoplasmacytic lymphoma). Additional findings may include the following[6][8]:

  • The plasma cells in bone marrow may exhibit an aberrant kappa/lambda ratio
  • Kappa light chains, especially VκIV variable region, are overrepresented (68-80%) in LCDD
  • Gamma chains are most common in HCDD
  • Deletion of the CH1 constant domain leads to premature secretion and tissue deposition of heavy chain in HCDD
  • Somatic mutations of the variable regions of light chain or heavy chain increase the hydrophobicity and hence the propensity for tissue deposition of Ig

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: t(9;22)(q34;q11.2) EXAMPLE: 3'ABL1 / 5'BCR EXAMPLE: der(22) EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add reference)

Yes No Yes EXAMPLE:

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).


editv4:Chromosomal Rearrangements (Gene Fusions)
The content below was from the old template. Please incorporate above.
  • There is limited information on the genomic abnormalities of the plasma cells in light chain and heavy chain deposition disease
  • Patients with PCM presumably have similar genomic abnormalities to myelomas without Ig deposition, perhaps with a different prevalence
  • In one study[8], t(11;14)(q13;q32) IGH/CCND1 fusion is detected as the most common fusion (nearly 50%), comparing to only 15-20% in myeloma without Ig deposition


editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)
  • Due to limited studies, no genetic abnormalities are prognostic or predictive of treatment response
  • FISH detection of the potentially frequent t(11;14) IGH/CCND1 fusion in association with BCL2 overexpression may help guide the application of BCL2 blocking agents including venetoclax[11][12][13]

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

7

EXAMPLE: Loss EXAMPLE:

chr7:1- 159,335,973 [hg38]

EXAMPLE:

chr7

Yes Yes No EXAMPLE:

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

EXAMPLE:

8

EXAMPLE: Gain EXAMPLE:

chr8:1-145,138,636 [hg38]

EXAMPLE:

chr8

No No No EXAMPLE:

Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH
The content below was from the old template. Please incorporate above.

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE:

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns
The content below was from the old template. Please incorporate above.
  • Patients with PCM presumably have similar genomic abnormalities to myelomas without Ig deposition, perhaps with a different prevalence
  • In one study[8], t(11;14)(q13;q32) IGH/CCND1 fusion is detected as the most common fusion (nearly 50%), comparing to only 15-20% in myeloma without Ig deposition
  • In the same study[8], hyperdiploidy is detected only at 16%, comparing to ~60% in myeloma without Ig deposition

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well as either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable. Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Do not delete table.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations

EXAMPLE: TSG EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).


Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.

Epigenomic Alterations

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table. Do not delete table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the old template. Please incorporate above.

Genetic Diagnostic Testing Methods

Testing methods include those needed to diagnose the underlying condition, as well as those specifically needed to detect the offending Ig in liquid samples and tissues. The following methods of testing have been reported[5][6][7][8][9]:

  • Diagnosis relies on detection of monoclonal Ig deposition in tissues biopsy; fine needle aspiration is not enough for diagnosis
  • Because kidney is almost always affected, detecting linear Ig deposits predominantly along TBM and GBM under immunofluorescence (IF) and/or electron microscopy studies of the kidney biopsy is diagnostic
  • Diagnosis in other tissues relies more on immunohistochemistry, as electron microscopy is rarely used
  • Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), immunofixation, and serum free light-chain (SFLC), should be performed to identify the monoclonal Ig; abnormal rates are 64% by SPEP, 68% UPEP, and 99–100% by SFLC
  • Bone marrow aspiration and biopsy should be routinely performed to identify the lymphoproliferative clone
  • Chromosome analysis and fluorescent in situ hybridization (FISH) were performed only for a small portion of cases historically but are helpful for clonal identification

Familial Forms

  • N/A

Additional Information

  • Survival improves with early diagnosis and proteasome inhibitor (PI)-based treatment, autologous stem cell transplantation, and kidney transplantation[10][14]
  • Poor prognosis markers include old age, the presence of PCM, extrarenal (especially cardiac) involvement, poor response to initial treatment[7][15]
  • Elimination or reduction of the underlying B-cell proliferative neoplasms to control the aberrant Ig deposition is crucial for preventing disease progression[14][10]
  • Kidney transplantation has a very high recurrence rate without controlling the monoclonal gammopathy[16]

Links


References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. ↑ McKenna RW, et al., (2017). Plasma cell neoplasms: Light chain and heavy chain deposition diseases, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p255-256.
  2. ↑ Sethi, Sanjeev; et al. (2018-07). "The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases". Journal of the American Society of Nephrology: JASN. 29 (7): 1810–1823. doi:10.1681/ASN.2017121319. ISSN 1533-3450. PMC 6050917. PMID 29703839. Check date values in: |date= (help)
  3. ↑ Leung, Nelson; et al. (2019-01). "The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group". Nature Reviews. Nephrology. 15 (1): 45–59. doi:10.1038/s41581-018-0077-4. ISSN 1759-507X. PMC 7136169 Check |pmc= value (help). PMID 30510265. Check date values in: |date= (help)
  4. ↑ Leung, Nelson; et al. (2021-05-20). "Monoclonal Gammopathy of Renal Significance". The New England Journal of Medicine. 384 (20): 1931–1941. doi:10.1056/NEJMra1810907. ISSN 1533-4406. PMID 34010532 Check |pmid= value (help).
  5. ↑ 5.0 5.1 5.2 5.3 Pozzi, Claudio; et al. (2003-12). "Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors". American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 42 (6): 1154–1163. doi:10.1053/j.ajkd.2003.08.040. ISSN 1523-6838. PMID 14655186. Check date values in: |date= (help)
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 Nasr, Samih H.; et al. (2012-02). "Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution". Clinical journal of the American Society of Nephrology: CJASN. 7 (2): 231–239. doi:10.2215/CJN.08640811. ISSN 1555-905X. PMID 22156754. Check date values in: |date= (help)
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Joly, Florent; et al. (2019-02-07). "Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study". Blood. 133 (6): 576–587. doi:10.1182/blood-2018-09-872028. ISSN 1528-0020. PMID 30578255.
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 Kourelis, Taxiarchis V.; et al. (2016-11). "Outcomes of patients with renal monoclonal immunoglobulin deposition disease". American Journal of Hematology. 91 (11): 1123–1128. doi:10.1002/ajh.24528. ISSN 1096-8652. PMID 27501122. Check date values in: |date= (help)
  9. ↑ 9.0 9.1 9.2 Mohan, Meera; et al. (2017-08). "Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease". American Journal of Hematology. 92 (8): 739–745. doi:10.1002/ajh.24756. ISSN 1096-8652. PMID 28383130. Check date values in: |date= (help)
  10. ↑ 10.0 10.1 10.2 Sayed, Rabya H.; et al. (2015-12-24). "Natural history and outcome of light chain deposition disease". Blood. 126 (26): 2805–2810. doi:10.1182/blood-2015-07-658872. ISSN 1528-0020. PMC 4732758. PMID 26392598.
  11. ↑ Szita, Virág Réka; et al. (2022). "Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers". Pathology oncology research: POR. 28: 1610276. doi:10.3389/pore.2022.1610276. ISSN 1532-2807. PMC 8918485 Check |pmc= value (help). PMID 35295611 Check |pmid= value (help).
  12. ↑ Bal, Susan; et al. (2022). "Multiple myeloma with t(11;14): unique biology and evolving landscape". American Journal of Cancer Research. 12 (7): 2950–2965. ISSN 2156-6976. PMC 9360221 Check |pmc= value (help). PMID 35968339 Check |pmid= value (help).
  13. ↑ Chakraborty, Rajshekhar; et al. (2022-10). "How do we manage t(11;14) plasma cell disorders with venetoclax?". British Journal of Haematology. 199 (1): 31–39. doi:10.1111/bjh.18243. ISSN 1365-2141. PMID 35594184 Check |pmid= value (help). Check date values in: |date= (help)
  14. ↑ 14.0 14.1 Cohen, Camille; et al. (2015-11). "Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease". Kidney International. 88 (5): 1135–1143. doi:10.1038/ki.2015.201. ISSN 1523-1755. PMID 26176826. Check date values in: |date= (help)
  15. ↑ Angel-Korman, Avital; et al. (2020-04). "The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease". Kidney International Reports. 5 (4): 485–493. doi:10.1016/j.ekir.2020.01.011. ISSN 2468-0249. PMC 7136323 Check |pmc= value (help). PMID 32274452 Check |pmid= value (help). Check date values in: |date= (help)
  16. ↑ Said, Samar M.; et al. (2018-07). "Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft". Kidney International. 94 (1): 159–169. doi:10.1016/j.kint.2018.01.028. ISSN 1523-1755. PMID 29716794. Check date values in: |date= (help)

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome. *Citation of this Page: “Monoclonal immunoglobulin deposition disease”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 09/6/2024, https://ccga.io/index.php/HAEM5:Monoclonal_immunoglobulin_deposition_disease.

Retrieved from "https://ccga.io/index.php?title=HAEM5:Monoclonal_immunoglobulin_deposition_disease&oldid=15332"